Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, announced today it has established a second commercial agreement with Weill Cornell Medicine. The agreement brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center through a trial led by renowned neurosurgeon, Roger Härtl, MD, the founder and director of the Weill Cornell Medicine Center for Comprehensive Spine Care and co-director of Och Spine at NewYork-Presbyterian. The trial is entitled "Bone Marrow Aspirate Concentrate Injection with MRI's - a Prospective Randomized Controlled Trial," conducted under IRB Protocol No. 24-09027977.

The purpose of this study is to evaluate the long-term effects of lumbar microdiscectomy surgery with and without an intradiscal bone marrow aspirate concentrate (BMAC) injection on patient reported outcomes, intervertebral disc (IVD) health (tissue hydration & composition), and pain biomarkers in a 2-year prospective study. The aim is to learn more about the natural history of degenerative disc disease (DDD), its causes, and inform its treatments.

This is the second trial at Weill Cornell Medicine to incorporate use of Nociscan.